Minerva Gastroenterol (Torino). 2026 Jan 29. doi: 10.23736/S2724-5985.25.04054-9. Online ahead of print.
ABSTRACT
Metabolic syndrome (MetS) is a complex and multifactorial condition that represents a major global health challenge. It is characterized by a cluster of interrelated metabolic abnormalities, including central obesity, insulin resistance, dyslipidemia, and hypertension, all of which substantially increase the risk of developing type 2 diabetes mellitus, cardiovascular diseases, and other related complications. Growing evidence underscores the pivotal role of the gut microbiota in regulating host metabolism, modulating immune responses, and influencing the chronic low-grade inflammatory state associated with MetS. Among emerging therapeutic approaches, synbiotics, defined as synergistic combinations of probiotics and prebiotics, have attracted considerable interest. Therefore, in the present narrative review, we aim to find out the feasibility and effectiveness of synbiotic supplements, as well as to evaluate their impact on people with MetS. By selectively stimulating the growth and activity of beneficial microbial taxa while directly introducing health-promoting strains, synbiotics may restore microbial balance, improve metabolic homeostasis, and attenuate inflammatory pathways. Future research should prioritize personalized nutrition strategies and microbiome-tailored interventions, taking into account individual variability in gut microbial composition and host metabolic responses. Such precision approaches could optimize synbiotic efficacy and safety, positioning them as a viable adjunctive treatment for MetS within an integrated lifestyle and pharmacological framework. Ultimately, large-scale, high-quality randomized controlled trials are essential to confirm current promising findings and to establish clear guidelines for clinical application.
PMID:41607348 | DOI:10.23736/S2724-5985.25.04054-9